The University of Oxford and Harrington Discovery Institute based at University Hospitals, Cleveland, Ohio, have formed a unique partnership combining world-leading strengths in research and therapeutics development, to form the Oxford-Harrington Rare Disease Centre (OHC). The OHC will set the science and innovation agenda, driving cutting-edge rare disease breakthroughs to address the unmet need in rare disease across the globe to deliver major clinical impact for patients.
University of Oxford
The University of Oxford ranks number one in the Times Higher Education World University Rankings (2017 to 2021), and its Medical Sciences Division is consistently at the forefront of innovative and lifesaving science. The University has more than 250 principal investigator scientists working on over 350 rare diseases and cutting-edge technologies to accelerate drug development.
Harrington Discovery Institute
Since 2012, the Harrington Discovery Institute brings expert knowledge and capability to develop medicines. Harrington has supported more than 150 drugs-in-the-making across disease areas and academic institutions, with a concentration in diseases where unmet need is greatest. Harrington houses a Therapeutics Development Center, which hosts a team of scientific, pharmaceutical, and drug development experts who have led many drugs to market in the pharma and biotech sectors. Harrington advances promising discoveries into the clinic by aligning scientific and drug discovery expertise into a uniquely successful, new model for medical breakthroughs.